KMDA
Kamada Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$7.76
−0.89%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$7.86
From 52W high−16.65%
Volume41628.00
Market cap$447.83M
P/E (TTM)20.3x
P/S (TTM)2.3x
Div yield4.61%
Key dataOct 16, 2026
Open
$7.86
From 52W high
−16.65%
Volume
41628.00
Market cap
$447.83M
ValuationView details →
P/E (Fwd)
16.9x
EV/EBITDA
9.3x
P/E (TTM)
20.3x
RSI (14)
42.5
MomentumView details →
1D Return
−0.89%
YTD Return
+9.92%
SummaryUpdated Jun 1, 2026
Kamada Ltd. (NASDAQ:KMDA) is an Israeli biopharmaceutical company founded in 1990 and headquartered in Rehovot, Israel. The company went public on NASDAQ in 2013 and has transformed from a single-product dependency into a diversified plasma-derived therapeutics company. Kamada specializes in developing, manufacturing, and commercializing plasma-derived protein therapeutics, primarily targeting rare diseases and immune-related conditions. The company operates through two main business segments: Proprietary Products and Distribution, with a growing focus on the U.S. market which now represents approximately 60-70% of its revenues.
Similar companies
Latest newsMore news →